Atezolizumab plus chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent
- Have non-squamous NSCLC (not squamous) that is resectable (removable) with curative surgery
- Your cancer stage must be stage II, IIIA, or a limited type of IIIB (T3N2 only as specified)
- Have a good performance status (ECOG 0 or 1) and measurable disease on scans
- Have enough lung and heart function for the planned lung surgery and provide tumor tissue from the primary tumor before starting treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.